[go: up one dir, main page]

SG11201601306QA - An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease - Google Patents

An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Info

Publication number
SG11201601306QA
SG11201601306QA SG11201601306QA SG11201601306QA SG11201601306QA SG 11201601306Q A SG11201601306Q A SG 11201601306QA SG 11201601306Q A SG11201601306Q A SG 11201601306QA SG 11201601306Q A SG11201601306Q A SG 11201601306QA SG 11201601306Q A SG11201601306Q A SG 11201601306QA
Authority
SG
Singapore
Prior art keywords
alzheimer
disease
treatment
receptor antagonist
cholinesterase inhibitor
Prior art date
Application number
SG11201601306QA
Inventor
Pascal Barneoud
Sophie Claudel
Philippe Delay-Goyet
Mathilde Lopez-Grancha
Jeremy Pratt
Jeanne Stemmelin
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201601306QA publication Critical patent/SG11201601306QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201601306QA 2013-09-09 2014-09-09 An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease SG11201601306QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306228 2013-09-09
PCT/EP2014/069168 WO2015032966A1 (en) 2013-09-09 2014-09-09 An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
SG11201601306QA true SG11201601306QA (en) 2016-03-30

Family

ID=49230670

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201601306QA SG11201601306QA (en) 2013-09-09 2014-09-09 An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Country Status (7)

Country Link
US (1) US20160256449A1 (en)
EP (1) EP3043799A1 (en)
JP (1) JP2016529307A (en)
KR (1) KR20160048930A (en)
CN (1) CN105764510A (en)
SG (1) SG11201601306QA (en)
WO (1) WO2015032966A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647377A1 (en) * 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
SI3500253T1 (en) 2016-08-18 2020-10-30 Suven Life Sciences Limited Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
NZ761037A (en) * 2017-07-03 2022-10-28 Suven Life Sciences Ltd New uses of a pure 5-ht6 receptor antagonist
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
EP3973586A4 (en) * 2019-05-21 2023-01-11 La Pharma Tech Inc. Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870846B1 (en) * 2004-05-25 2006-08-04 Sanofi Synthelabo TETRAHYDROISOQUINOLYLSULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
JP2009541423A (en) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ Combination of a cholinesterase inhibitor and a compound having affinity for 5-HT6 receptor
CA2766154C (en) * 2009-06-26 2015-04-07 Beverly C. Langevin Novel fumarate salts of a histamine h3 receptor antagonist
FR2953521B1 (en) * 2009-12-09 2011-11-18 Servier Lab NOVEL AZABICYCLO [3.1.0] HEX-2-YL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR080374A1 (en) * 2010-03-05 2012-04-04 Sanofi Aventis PROCEDURE FOR THE PREPARATION OF 2- (CYCLOHEXILMETIL) -N- (2 - ((2S) -1-METHYLPIRROLIDIN-2-IL) ETIL) - 1,2,3,4-TETRAHYDROISOQUINOLIN-7- SULFONAMIDE
FR2976286B1 (en) * 2011-06-08 2013-05-24 Servier Lab 4- {3- [TRANS-HEXAHYDROCYCLOPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} BENZAMIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP2647377A1 (en) * 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
EP2745876A1 (en) * 2012-12-21 2014-06-25 Prous Institute for Biomedical Research, S.A. Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives

Also Published As

Publication number Publication date
EP3043799A1 (en) 2016-07-20
WO2015032966A1 (en) 2015-03-12
JP2016529307A (en) 2016-09-23
KR20160048930A (en) 2016-05-04
CN105764510A (en) 2016-07-13
US20160256449A1 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
SG11202012656WA (en) Heterocyclic compounds useful in the treatment of disease
IL285843A (en) Ibrutinib for use in the treatment of graft-versus-host disease
IL243976A0 (en) Kdm1a inhibitors for the treatment of disease
PL2968218T3 (en) Combination for the treatment of parkinson's disease
EP3019491A4 (en) Kinase inhibitors for the treatment of disease
GB201321743D0 (en) Therapeutic agents
GB201321746D0 (en) Therapeutic agents
GB201321738D0 (en) Therapeutic Agents
PL3811943T3 (en) Compound for use in the treatment of ocular disorders
GB201321736D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
EP2882439A4 (en) AGENTS INDUCING APOPTOSIS
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
GB201321728D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321741D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
GB201321744D0 (en) Therapeutic agents
GB201321737D0 (en) Therapeutic Agents
GB201321742D0 (en) Therapeutic agents